Free Trial
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$28.15 +0.55 (+1.99%)
(As of 05:19 PM ET)

About Hims & Hers Health Stock (NYSE:HIMS)

Key Stats

Today's Range
$27.37
$28.29
50-Day Range
$18.85
$34.23
52-Week Range
$8.09
$35.02
Volume
4.48 million shs
Average Volume
10.06 million shs
Market Capitalization
$6.15 billion
P/E Ratio
63.98
Dividend Yield
N/A
Price Target
$22.80
Consensus Rating
Hold

Company Overview

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

Hims & Hers Health Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 69% of companies evaluated by MarketBeat, and ranked 328th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 8 buy ratings, 8 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 72.41% in the coming year, from $0.29 to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is 63.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.14.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is 63.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.65.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 17.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    24.04% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.04% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Hims & Hers Health this week, compared to 14 articles on an average week.
  • Search Interest

    Only 74 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • MarketBeat Follows

    38 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 41% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold 20,653.64% more of their company's stock than they have bought. Specifically, they have bought $132,260.00 in company stock and sold $27,448,767.00 in company stock.

  • Percentage Held by Insiders

    17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Stock News Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Stuttgart, Germany - 07-08-2024: Mobile phone with webpage of US online education company Stride Inc. in front of business logo. Focus on top-left of phone display. — Stock Editorial Photography
4 Stocks That Crushed Analyst Estimates by More Than Double
Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.
Hims & Hers: Still Trading At A Massive Discount
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS shares have increased by 216.3% and is now trading at $28.15.
View the best growth stocks for 2024 here
.

Hims & Hers Health, Inc. (NYSE:HIMS) issued its quarterly earnings results on Monday, November, 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The company's quarterly revenue was up 77.1% compared to the same quarter last year.

Hims & Hers Health's top institutional shareholders include State Street Corp (2.15%), Geode Capital Management LLC (2.00%), Wellington Management Group LLP (1.60%) and Connor Clark & Lunn Investment Management Ltd. (0.79%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Patrick Harrison Carroll, Michael Chi, Soleil Boughton, Oluyemi Okupe, Jules A Maltz, Christopher D Payne, Andrew Dudum, Christiane Pendarvis, Irene Becklund, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/04/2024
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
Healthcare
Fax
N/A
Employees
1,046
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.80
High Stock Price Target
$42.00
Low Stock Price Target
$10.00
Potential Upside/Downside
-19.0%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
17 Analysts

Profitability

Net Income
$-23,550,000.00
Pretax Margin
4.16%

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Book Value
$1.61 per share

Miscellaneous

Free Float
179,786,000
Market Cap
$6.15 billion
Optionable
Optionable
Beta
1.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:HIMS) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners